natgillin/translations-raw huggingface dataset:
Therefore, data from higher dose of NETA or other progestogens may not be extrapolated to the NETA 0.1 mg dose.
Zaradi tega podatkov za višje odmerke NETA ali druge progestogene ni mogoče ekstrapolirati na odmerek 0,1 mg NETA.
Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-I-antitrypsin, and ceruloplasmin).
Zvišajo se lahko druge beljakovine v plazmi (angiotenzinogen/reninski substrat, alfa-I-antitripsin, ceruloplazmin).
c. Continuous combined therapy versus sequential therapy in the prevention of endometrial hyperplasia or carcinoma
c. Kontinuirano kombinirano zdravljenje v primerjavi s sekvenčnim zdravljenjem pri preprečevanju hiperplazije endometrija ali karcinoma
Thus, in spite of the dose-related increase in incidence of hyperplasia, data could be considered insufficient to draw definite conclusions regarding endometrial safety of E2 0.5 mg.
Zato, kljub povečanju pojavnosti od odmerka odvisne hiperplazije, podatki ne zadostujejo za oblikovanje jasnih zaključkov glede endometrijske varnosti 0,5 mg E2.
How to use the calendar pack
Navodilo za uporabo koledarskega pakiranja
• If you have a blood clot (like deep vein thrombosis or lung embolism) or previously have had a blood clot without obvious cause, e.g. in connection with surgery or pregnancy
• imate krvni strdek (npr. globoko vensko trombozo ali pljučno embolijo) ali ste takšen strdek imeli kdaj v preteklosti in brez očitnega vzroka, npr. v povezavi z operacijo ali nosečnostjo,
• If you have recently had a heart attack, stroke, or have angina
• ste pred nedavnim imeli srčni infarkt, možgansko kap ali imate angino pektoris,
T3 resin uptake is decreased, reflecting the elevated TBG.
Vezava T3 na smolo je zmanjšana, kar je posledica zvišanja TBG.
Activelle contains lactose monohydrate.
Zdravilo Activelle vsebuje laktozo monohidrat.
• If you have high levels of fat in the blood (hypertriglyceridemia)
• če imate visoko koncentracijo maščob v krvi (hipertrigliceridemijo),
Patients with a history of VTE or known thrombophilic states have an increased risk of VTE.
Bolnice z anamnezo VTE ali znanimi trombofilnimi stanji imajo večje tveganje za VTE.
Two large clinical trials (WHI and HERS i.e. Heart and Estrogen/progestin Replacement Study) showed a possible increased risk of cardiovascular morbidity in the first year of use and no overall benefit.
Dve veliki klinični preskušanji (WHI in HERS, tj. Heart and Estrogen/progestin Replacement Study) sta pokazali, da se lahko tveganje za srčnožilno obolevnost v prvem letu uporabe poveča, ne da bi hkrati zdravljenje v celoti kaj koristilo.
It should be taken into account that these conditions may recur or be aggravated during treatment with Activelle in particular:
Upoštevati je treba, da se lahko med zdravljenjem z zdravilom Activelle ponovijo ali poslabšajo zlasti naslednja stanja:
The addition of a progestagen for at least 12 days per cycle in non-hysterectomised women greatly reduces this risk.
Pri nehisterektomiranih ženskah dodajanje progestagena vsaj 12 dni v ciklu močno zmanjša to tveganje.
These data, along with data on effects on endometrial hyperplasia, convincingly support the assumption that a continuous combined regimen protects the endometrium from both hyperplasia and neoplasia, a protective effect that seems to be both relative and absolute (i.e. conferring a lower risk than for untreated women) and that seems to increase with duration of intake.
Ti podatki skupaj s podatki o učinkih na hiperplazijo endometrija prepričljivo podpirajo domnevo, da kontinuirano kombinirano zdravljenje ščiti endometrij pred hiperplazijo in neoplazijo, ta zaščitni učinek pa se zdi relativen in absoluten (tj. ima za posledico manjše tveganje kot pri nezdravljenih ženskah) ter da se veča s trajanjem časa jemanja zdravila.
The metabolism of oestrogens and progestagens may be increased by concomitant use of substances known to induce drug-metabolising enzymes, specifically cytochrome P450 enzymes such as anticonvulsants (e.g. phenobarbital, phenytoin, carbamazepin) and anti-infectives (e.g. rifampicin, rifabutin, nevirapine, efavirenz).
Presnovo estrogenov in progestagenov lahko poveča sočasna uporaba snovi, ki inducirajo encime za presnovo zdravil, zlasti encime citokroma P450; med takšnimi so antiepileptiki (npr. fenobarbital, fenitoin, karbamazepin) in antiinfektivi (npr. rifampicin, rifabutin, nevirapin, efavirenz).
If you get:
Če se pojavijo:
[To be completed nationally]
[Izpolni država članica]
It can also be noticed that the monitoring of the endometrial thickness by pelvic ultrasound showed a significant increase, even with 0.5 mg E2, which was not reported in the placebo group.
Izpostaviti je treba tudi, da je pelvično ultrazvočno opazovanje endometrijske debeline pokazalo znatno povečanje tudi pri odmerkih 0,5 mg E2, o čemer v skupini, ki je prejemala placebo, niso poročali.
Novo Nordisk Pharmaceutique S.A. 30 Rue De Valmy FR-92936 Paris La Defence Cedex France
30 Rue De Valmy FR-92936 Paris La Defence Cedex Francija comprimé pelliculé
• Regularly check your breasts for any changes, such as dimpling or sinking of the skin, changes in the nipple, or any lumps you can see or feel
• na redno samopregledovanje dojk, namenjeno odkrivanju sprememb, npr. nagubanosti ali udrtosti kože, sprememb na bradavici ali bul, ki jih lahko vidite ali otipljete,
It states that “for a new combination of oestrogen/progestogen (e.g. new administration scheme or new strength) or a new progestogen in a fixed combination, endometrial data are required, except for a known progestogen, with the same administration route and the same progestogen dose as in known fixed combination with oestrogen, where data on endometrial safety can be extrapolated from the fixed combination if exposure to the oestrogen is similar or lower”.
Smernice navajajo, da so „za novo kombinacijo estrogena/progestogena (npr. nova shema dajanja zdravila ali nova jakost) ali novo količino progestogena v fiksni kombinaciji potrebni podatki o endometriju, z izjemo za znane količine progestogena ob isti poti uporabe in istemu odmerku progestogena kot pri znani fiksni kombinaciji z estrogenom, kjer je podatke o endometrijski varnosti mogoče ekstrapolirati iz fiksne kombinacije, če je izpostavljenost estrogenu podobna ali nižja“.
Taking into account the points above, the some CHMP were of the opinion that endometrial safety of Activelle 0.5 mg/0.1 mg could not be supported by the KLIM/PD/7/USA trial.
Ob upoštevanju zgoraj naštetih točk so bili nekateri člani CHMP mnenja, da endometrijske varnosti zdravila Activelle 0,5 mg/0,1 mg ni mogoče podpreti s preskušanjem KLIM/PD/7/USA.
Very common side effects • Vaginal bleeding.
Zelo pogosti neželeni učinki • krvavitev iz nožnice
USER INSTRUCTIONS
NAVODILO ZA UPORABNICO
If you want to stop taking Activelle, talk to your doctor first.
Če želite opustiti jemanje zdravila Activelle, se najprej posvetujte z zdravnikom.
It substitutes for the loss of oestrogen production in menopausal women, and alleviates menopausal symptoms.
Nadomešča upad nastajanja estrogena pri ženskah v menopavzi in blaži menopavzne simptome.
Amenorrhoea (no bleeding or spotting) was seen in 89% of the women in month 6 of treatment.
V 6. mesecu zdravljenja je imelo amenorejo (nobenih krvavitev ali krvavkastega izcedka) 89 % žensk.
Therefore, it is uncertain whether these findings also extend to other HRT products.
Zato ni gotovo, ali ti izsledki veljajo tudi za druga zdravila za HNZ.
You can only turn the transparent dial after the tablet in the opening has been removed.
Prozorno kazalno ploščico je mogoče zavrteti naprej šele, ko ste tableto vzeli iz odprtine.
According to the guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women (EMEA/CHMP/021/97 Rev. 1) endometrial safety has to be demonstrated unequivocally before approval.
Skladno s smernicami za klinično preskušanje zdravil za hormonsko nadomestno zdravljenje simptomov pomanjkanja estrogena pri ženskah v obdobju postmenopavze (EMEA/CHMP/021/97 Rev. 1) je treba pred odobritvijo nedvoumno dokazati endometrijsko varnost.
Moreover, one endometrial sample from a woman who received the E2 1 mg/NETA 0.1 mg combination was evaluated as “disordered proliferative” state.
Poleg tega so enega od vzorcev endometrija, odvzetega ženski, ki je prejemala kombinacijo 1 mg E2/0,1 mg NETA, ocenili kot „moteno proliferativno“ stanje.
Adding a progestagen, such as in Activelle, greatly reduces this increased risk.
Dodatek progestagena, kot ga vsebuje zdravilo Activelle, močno zmanjša to povečanje tveganja.
Patients with terminal renal insufficiency should be closely observed, since it is expected that the level of circulating active ingredients in Activelle will increase.
Bolnice s končno odpovedjo ledvic je treba natančno spremljati, ker je treba pričakovati, da se bo koncentracija učinkovin zdravila Activelle v obtoku povečala.
In addition to the above mentioned adverse drug reactions, those presented below have been spontaneously reported, and are by an overall judgement considered possibly related to Activelle 1 mg/0.5 mg treatment.
Poleg zgoraj navedenih neželenih učinkov na zdravilo so bile spontano prijavljene spodaj opisane; po splošni presoji so lahko povezane z uporabo zdravila Activelle 1 mg/0,5 mg.
There was no significant difference in the rate of endometrial hyperplasia of continuous oestrogenprogestogen combinations in comparison with placebo after 12 and 24 months.
Razlike v stopnji hiperplazije endometrija med kontinuiranimi kombinacijami estrogena in progestogena v primerjavi s placebom po 12 in 24 mesecih niso bile pomembne.
The risk seems to be higher for women, who use oestrogen in combination with progestagen as compared to oestrogen alone.
Kot kaže, je tveganje večje pri ženskah, ki uporabljajo estrogen v kombinaciji s progestagenom, kakor pri tistih, ki uporabljajo samo estrogen.
If more than 12 hours have gone by, start again as normal the next day.
Če je minilo že več kot 12 ur od tedaj, ko bi morali vzeti tableto, nadaljujte z jemanjem naslednji dan kot ponavadi.
Animal studies have shown embryo-lethal effects of estradiol or estradiol valerate even at relatively low doses; malformations of the urogenital tract and feminization of male fetuses were observed.
Pri eksperimentalnih živalih sta estradiol ali estradiolvalerat že v razmeroma majhnih odmerkih učinkovala embrioletalno; opažali so malformacije urogenitalnega trakta in feminizacijo moških plodov.
However, the some members of the CHMP noted that this trial failed to demonstrate the endometrial safety of the combination of E2 1 mg and NETA 0.1 mg, as the upper limit of the two-sided 95% confidence interval of the observed frequency of endometrial hyperplasia was 2.90% and then exceeded the acceptable limit of 2%.
Vendar pa so nekateri člani CHMP opazili, da s tem preskušanjem niso uspeli dokazati endometrijske varnosti kombinacije 1 mg E2 in 0,1 mg NETA, ker je bila zgornja meja dvostranskega 95 % intervala zaupanja ugotovljene pogostosti hiperplazije endometrija enaka 2,90 % in je tako presegala sprejemljivo mejo 2 %.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Če kateri koli neželeni učinek postane resen ali če opazite kateri koli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
Active substances that inhibit the activity of hepatic microsomal drug metabolizing enzymes e.g. ketoconazole, may increase circulating levels of the active substances in Activelle.
Učinkovine, ki zavrejo aktivnost jetrnih mikrosomskih encimov, udeleženih v presnovi zdravil, npr. ketokonazol, lahko povečajo koncentracijo učinkovin zdravila Activelle v obtoku.
HRT, especially oestrogen-progestagen combined treatment, may increase the density of mammographic images which may adversely affect the radiological detection of breast cancer.
HNZ, zlasti kombinirano estrogensko-progestagensko zdravljenje, povečuje gostoto na mamografskih posnetkih; to lahko neugodno vpliva na radiološko odkrivanje raka na dojki.
• Porphyria
• porfirija.
• Medicines used for tuberculosis (such as rifampicin, rifabutin)
• zdravila proti tuberkulozi (npr. rifampicin, rifabutin),
A randomised placebo-controlled trial, the Women's Health Initiative study (WHI), and epidemiological studies, including the Million Women Study (MWS), have reported an increased risk of breast cancer in women taking oestrogens, oestrogen-progestagen combinations or tibolone for HRT for several years (see section 4.8).
V randomiziranem, s placebom kontroliranem preskušanju WHI (Women's Health Initiative) in v epidemioloških študijah, vključno s študijo MWS (Million Women Study), so ugotovili večje tveganje za raka na dojki pri ženskah, ki so za HNZ več let jemale estrogene, estrogensko-progestagenske kombinacije ali tibolon (glejte poglavje 4.8).
- on the level of endometrial hyperplasia, the trial on the 1 mg estradiol/0.1 mg NETA product indicates an adequate protective effect, albeit with an upper confidence limit of the hyperplasia rate estimate exceeding recommendation in the guideline.
- o stopnji hiperplazije endometrija, preskušanje z zdravilom, ki vsebuje 1 mg estradiola/0,1 mg NETA, kaže primeren zaščitni učinek, čeprav ocena zgornje meje zaupanja za stopnjo hiperplazije presega priporočilo v smernicah,
1 x 28 film-coated tablets 3 x 28 film-coated tablets
1 x 28 filmsko obloženih tablet 3 x 28 filmsko obloženih tablet
HRT is associated with a higher relative risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism.
HNZ je povezano z večjim relativnim tveganjem za vensko trombembolijo (VTE), tj. globoko vensko trombozo ali pljučno embolijo.
For other HRT products there are only limited data from randomised controlled trials examining effects in cardiovascular morbidity or mortality.
O drugih zdravilih za HNZ je le malo podatkov iz randomiziranih kontroliranih preskušanj, ki so proučevala učinke na srčnožilno obolevnost ali umrljivost.
• Systemic lupus erythematosus
• sistemski eritematozni lupus,
• Epilepsy
• epilepsija,
Ritonavir and nelfinavir, although known as strong inhibitors, by contrast exhibit inducing properties when used concomitantly with steroid hormones.
Ritonavir in nelfinavir, ki sta sicer znana kot močna zaviralca, med sočasno uporabo s steroidnimi hormoni delujeta nasprotno, kot induktorja.
At high doses of norethisterone embryo-lethal effects were observed.
Po velikih odmerkih noretisterona so opažali embrioletalne učinke.
Data on a limited number of exposed pregnancies indicate adverse effects of norethisterone on the foetus.
Podatki, zbrani pri omejenem številu nosečnic, izpostavljenih zdravilu, kažejo na možnost škodljivih vplivov noretisterona na plod.
In women transferring from sequential HRT regimens, treatment should start right after their withdrawal bleeding has ended.
Pri ženskah, ki preidejo s sekvenčnih shem za HNZ, se mora zdravljenje začeti takoj po koncu odtegnitvene krvavitve.
If you forget to take Activelle
Če ste pozabili vzeti zdravilo Activelle
- Pooled data from several recently authorized sequential and continuous oestrogen/progestin HRT combinations in Europe show that the incidence of hyperplasia or more serious adverse endometrial outcomes was approximately 0.26% during the first year of treatment, that is well under the observed hyperplasia incidence of 0.8% in the KLIM/PD/7/USA trial.
- Podatki, zbrani iz več v Evropi nedavno odobrenih kombinacij estrogena/progestina za sekvenčno ali kontinuirano HNZ kažejo, da je pojavnost hiperplazije ali resnejših neželenih endometrijskih rezultatov znašala približno 0,26 % v prvem letu zdravljenja, kar je precej nižje od pojavnosti hiperplazije v preskušanju KLIM/PD/7/USA, kjer je ta znašala 0,8 %.
a. the proliferative effect of unopposed oestrogens on the endometrium is dose-dependant, b. this proliferative effect of unopposed oestrogens is time-dependant, especially for high oestrogen doses, c. continuous combined therapy over long duration is more protective that sequential therapy in the prevention of endometrial hyperplasia or carcinoma.
a. proliferativni učinek estrogenov, ki niso modificirani z učinki progestogena, na endometrij je odvisen od odmerka, b. ta proliferativni učinek estrogenov, ki niso modificirani z učinki progestogena, je časovno pogojen še posebej pri visokih odmerkih estrogena, c. dolgoročna kontinuirana kombinirana terapija omogoča pri preprečevanju endometrijske hiperplazije ali karcinoma večjo zaščito kot sekvenčna terapija.
It undergoes first-pass metabolism in the liver and other enteric organs, and reaches a peak plasma concentration of approximately 2.4 ng/ml CV 41 % (after administration of two Activelle tablets) within 0.5 -1.5 hour.
Podvržen je presnovi prvega prehoda v jetrih in drugih enteričnih organih; največjo koncentracijo v plazmi - približno 2,4 ng/ml (KV 41 %) - doseže (po uporabi dveh tablet Activelle) v 0,5 do 1,5 ure.
The sample size of the KLIM/PD/11/USA study may be considered too small to draw any definite conclusion regarding endometrial safety of E2 0,5 mg, even for 2 yeartreatment.
Velikost vzorca v študiji KLIM/PD/11/USA lahko razumemo kot premajhno, da bi lahko prišli do jasnih zaključkov glede endometrijske varnosti 0,5 mg E2, tudi če zdravljenje traja dve leti.
- The endometrial safety data is not in accordance with the European guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in post menopausal women (EMEA/CHMP/021/97 rev1).
- Podatki o endometrijski varnosti niso skladni z evropskimi smernicami o kliničnem preskušanju zdravil za hormonsko nadomestno zdravljenje simptomov pomanjkanja estrogena pri ženskah v postmenopavzalnem obdobju (EMEA/CHMP/021/97 rev 1).
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Če imate dodatna vprašanja o uporabi zdravila Activelle, se posvetujte z zdravnikom ali s farmacevtom.
• Psychiatric disorders: Insomnia, anxiety, libido decreased, libido increased
• Psihiatrične motnje: nespečnost, anksioznost, zmanjšanje libida, zvečanje libida
According to data from epidemiological studies, the best estimate of the risk is that for women not using HRT about 5 in every 1000 are expected to have endometrial cancer diagnosed between the ages of 50 and 65.
Po podatkih epidemioloških študij je najboljša ocena tveganja, da je mogoče med neuporabnicami HNZ pričakovati diagnosticiranega raka na endometriju v starosti od 50 do 65 let pri približno 5 na 1.000 žensk.
You may be at risk of having a blood clot if you get:
Nevarnost, da imate krvni strdek, obstaja, če se vam pojavijo:
This risk increases with the duration of intake of HRT, but returns to normal within a few (at most five) years of having stopped HRT.
Tveganje se povečuje s trajanjem HNZ, a se normalizira v nekaj (največ petih) letih po koncu HNZ.
Taking the above arguments on board, the majority of CHMP members were of the opinion that the data presented demonstrate the importance of types of oestrogen-progestogen regimens for the association with endometrial cancer risk.
Večina članov CHMP je bila ob upoštevanju zgoraj navedenih argumentov mnenja, da predstavljeni podatki kažejo pomembnost vrst režimov zdravljenja s kombinacijo estrogena in progestogena za povezavo s tveganjem pojava raka endometrija.
However, the CHMP noted that the strengths studied did not include E2 0.5 mg/NETA 0.1 mg.
Vendar pa je CHMP ugotovil, da raziskovane jakosti niso vključevale 0,5 mg E2/0,1 mg NETA.
- For the calculation of the incidence rate of endometrial hyperplasia and the two-sided 95 % confidence interval, in case of insufficient tissue obtained by biopsy and endometrial thickness ≥ 5 mm, the biopsy should be repeated or patient excluded from the calculation.
- Za izračun ravni pojavnosti hiperplazije endometrija in dvostranskega 95 % intervala zaupanja je treba biopsijo ponoviti ali bolnico izključiti iz izračunov, če pri biopsiji niso zajeli zadostne količine tkiva in je debelina endometrijske plasti ≥ 5 mm.
For the treatment of postmenopausal symptoms, HRT should only be initiated for symptoms that adversely affect quality of life.
Za zdravljenje pomenopavznih simptomov je dovoljeno HNZ uvesti le, če ti simptomi neugodno vplivajo na kakovost življenja.
- the addition of a progestogen for 12 days of a monthly treatment cycle is considered sufficient to protect the endometrium from an excess risk of hyperplasia (and ultimately endometrial cancer), and even longer periods, and a continuous combination will confer increasing protective effects.
- da se dodajanje progestogena 12 dni ali dlje med celotnim mesečnim ciklom zdravljenja upošteva kot zadostno za zaščito endometrija pred čezmernim tveganjem pojava hiperplazije (in v končni fazi raka endometrija), ter kontinuirana kombinacija omogočita večanje zaščitnih učinkov,
• If any of your immediate family has had breast cancer, or other cancers related to oestrogen
• če je kdo od vaših bližnjih sorodnikov imel raka na dojki ali druge vrste raka, povezane z estrogenom (rak na endometriju),
Physical (including pelvic and breast) examination should be guided by this and, by the contraindications and warnings for use.
Klinični pregled (vključno z ginekološkim pregledom in pregledom dojk) se mora opirati na tako dobljene podatke ter na kontraindikacije in opozorila za uporabo.
However, if you are switching from an HRT product where you have monthly bleeding, start your treatment straight after the bleeding has ended.
Če pa ste doslej uporabljali zdravilo za HNZ, pri katerem ste imeli mesečne krvavitve, začnite zdravljenje z zdravilom Activelle takoj po koncu krvavitve.
DATE OF REVISION OF THE TEXT [To be completed nationally]
DATUM ZADNJE REVIZIJE BESEDILA [Izpolni država članica]
Do not use Activelle after the expiry date which is stated on the label and outer carton after “EXP”.
Zdravila Activelle ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na zunanji ovojnini za oznako "Upor.
• If you have or have had breast cancer, or if it is suspected
• imate ali ste kdaj imeli raka na dojki, ali če obstaja sum nanj,
In conclusion, the CHMP agreed that the proliferative effect of unopposed oestrogens on endometrium is dependent on the dose of oestrogens.
V zaključku se je CHMP strinjal, da so proliferativni učinki estrogenov, ki niso modificirani z učinki progestogena, na endometrij odvisni od odmerka estrogenov.
• If you develop yellow skin or eyes (jaundice) or other liver problems
• vam porumenijo koža ali očesna beločnica (zlatenica) ali se pojavijo druge težave z jetri,
• Diabetes mellitus with or without vascular involvement
• diabetes mellitus s prizadetostjo žil ali brez nje,
For all HRT, an excess risk becomes apparent within a few years of use and increases with duration of intake but returns to baseline within a few (at most five) years after stopping treatment.
Dodatno tveganje se pri vseh HNZ pokaže v nekaj letih uporabe in narašča s trajanjem jemanja, a se v nekaj (največ petih) letih po koncu zdravljenja vrne na izhodiščno raven.
• Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction)
• aktivna ali nedavna arterijska trombembolična bolezen (npr. angina pektoris, miokardni infarkt),
Estonia - Activelle low 0,5 mg/0,1 mg õhukese polümeerikattega tablett Finland - Activelle 0,5 mg/0,1 mg tabl.
Estonija - Activelle low 0,5 mg/0,1 mg õhukese polümeerikattega tablett Finska - Activelle 0,5 mg/0,1 mg tabl.
• Otosclerosis
• otoskleroza.
• Swelling of arms and legs (peripheral oedema)
• otekanje rok in nog (periferni edemi)
If pregnancy occurs during medication with Activelle, treatment should be withdrawn immediately.
Če ženska med uporabo zdravila Activelle zanosi, je treba zdravljenje takoj prekiniti.
What Activelle is and what it is used for Before you take Activelle How to use Activelle Possible side effects How to store Activelle Further information
Kaj je zdravilo Activelle in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Activelle Kako jemati zdravilo Activelle Možni neželeni učinki